Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÇilekar, Şule
dc.contributor.authorBalcı, Aydın
dc.contributor.authorCoşğun, İbrahim Güven
dc.date.accessioned2023-10-24T06:53:40Z
dc.date.available2023-10-24T06:53:40Z
dc.date.issued2022en_US
dc.identifier.citationÇilekar, Ş., BALCI, A., & COŞGUN, İ. G. (2022). Is COVID-19 responsible for asthma and COPD exacerbations?. Health Sciences Quarterly, 2(1), 17-25.en_US
dc.identifier.issn2791-6022
dc.identifier.urihttps://dx.doi.org/10.26900/hsq.2.1.03
dc.identifier.urihttps://hdl.handle.net/20.500.12933/1672
dc.description.abstractCOVID-19 is an infectious disease that is transmitted by the respiratory tract and was first identified in the Wuhan province of China. The causative agent of the disease is SARS-CoV-2. There is little known about this disease and its agent, which affected the whole world in a short time and became a pandemic. Molecular interactions between COVID-19 and chronic respiratory diseases are unknown. In this study, we examined the patients admitted to our outpatient clinic with the diagnosis of Asthma and Chronic Obstructive Pulmonary Disease (COPD) exacerbation. We investigated how much of the exacerbations during the pandemic period are caused by the COVID-19 virus and whether there have been any changes in the treatment of and approaches to exacerbations stemming from COVID-19. COVID-19 was detected in 135 of the patients. Clinically, fever, myalgia, and headache findings were significantly more common in patients with a positive COVID-19 PCR CoV 2 test in patients who were diagnosed with an attack of Asthma or exacerbation of COPD (p<0.001). The number of hospitalizations, the need for intensive care, the need for ventilation support, and the number of mortality were high in asthma and COPD patients with positiveSARS- CoV-2 tests (p<0.05 ). Based on the results of our study, patients with COPD and asthma exacerbations due to COVID-19 should be evaluated from a wider perspective. As is known, chronic diseases are poor prognostic factors for COVID-19, but asthma and COPD chronic disease are prominent among them. If there is a need for different approaches for the treatment of these patients, these approaches should be determined urgently.en_US
dc.language.isoengen_US
dc.publisherHolistence Publicationsen_US
dc.relation.isversionof10.26900/hsq.2.1.03en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOPD exacerbationen_US
dc.subjectAsthma Exacerbationen_US
dc.subjectCovid-19en_US
dc.titleIs COVID-19 responsible for asthma and COPD exacerbations?en_US
dc.typearticleen_US
dc.authorid0000-0001-8659-955Xen_US
dc.departmentAFSÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göğüs Cerrahisi Ana Bilim Dalıen_US
dc.contributor.institutionauthorÇilekar, Şule
dc.contributor.institutionauthorBalcı, Aydın
dc.contributor.institutionauthorCoşğun, İbrahim Güven
dc.identifier.volume2en_US
dc.identifier.issue1en_US
dc.identifier.startpage17en_US
dc.identifier.endpage25en_US
dc.relation.journalHealth sciences quarterlyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster